Tesevatinib tosylate is under clinical development by Kadmon and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tesevatinib tosylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tesevatinib tosylate overview
Tesevatinib tosylate (KD-019, XL647) is under development for the treatment of autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, non-small cell lung cancer with brain metastasis (or) leptomeningeal metastasis, recurrent glioblastoma multiforme. It is a small molecule administered orally. It acts by inhibiting the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor VEGFR 2 and 3 and ephrin B4 (EphB4) RTKs. It was under development for the treatment of non-small cell lung cancer, metastatic breast cancer, prostate cancer, metastatic or unresectable adenocarcinoma of esophagus, gastroesophageal junction and stomach cancer.
Kadmon is an integrated biopharmaceutical company that discovers, develops and markets small molecules and biologics for autoimmune and fibrotic diseases, various types of cancer, and genetic diseases. The company’s pipeline encompasses investigational candidates for the treatment of moderate to severe psoriasis, idiopathic pulmonary fibrosis, and polycystic kidney disease among others. Its pipeline candidates are based on its small molecule and biologics platforms. It also develops in-licensed product candidates and technologies. The company works in partnership with various pharmaceutical and biopharmaceutical companies to advance its pipeline candidates. Kadmon is headquartered in New York, the US.
For a complete picture of Tesevatinib tosylate’s drug-specific PTSR and LoA scores, buy the report here.